Skip to main content
. Author manuscript; available in PMC: 2013 Sep 25.
Published in final edited form as: J Am Coll Surg. 2011 Mar 23;212(5):880–888. doi: 10.1016/j.jamcollsurg.2011.01.006

Figure 3.

Figure 3

Histologic scores, separated by mesh type and length of time in vivo. (A) Cellular infiltration scores demonstrated that the non-crosslinked meshes (Veritas and AlloDerm) initially permitted more cellular infiltration than the crosslinked meshes (Permacoland Peri-Guard); p < 0.008. By 6 and 12 months, this trend disappeared and all meshes achieved equivalent cellular infiltration (p > 0.05). (B) Cell types scores revealed that fewer inflammatory cells and more fibroblasts were detected at 1 and 6 months in Peri-Guard compared with AlloDerm (p < 0.02), and all other comparisons at these time points were not significant (p > 0.05). By 12 months, Veritas exhibited the greatest number of fibroblasts and least inflammatory infiltrate compared with the other 3 materials (p < 0.04). (C) Extracellular matrix (ECM) deposition scores at 1 month demonstrated that the non-crosslinked meshes (Veritas and AlloDerm) initially permitted more cellular infiltration than the crosslinked meshes (Permacoland Peri-Guard); p < 0.02. At 6 months, Veritas, AlloDerm, and Permacol all demonstrated greater ECM deposition than Peri-Guard (p < 0.02), and by 12 months, the only remaining difference was that Veritas exhibited the highest level of ECM deposition compared with Peri-Guard and AlloDerm (p < 0.03). (D) Scaffold degradation scores showed that non-crosslinked meshes (Veritas and AlloDerm) were markedly more degraded at 1 and 6 months compared with the crosslinked meshes (Permacoland Peri-Guard); p < 0.03. Veritas also exhibited significantly more scaffold degradation than the other non-crosslinked mesh, AlloDerm, at both 1 and 6 months (p = 0.010 and p = 0.002, respectively). (E) Fibrous encapsulation scores revealed that Veritas was significantly less encapsulated (higher score means less encapsulation) than all other meshes at 1 month (p < 0.01). By 6 months, both non-crosslinked materials (AlloDerm and Veritas) scored similarly, and both were significantly less encapsulated than the crosslinked meshes (p < 0.001). However, at 12 months, the crosslinked meshes showed decreasing levels of encapsulation, suggesting that this process might be reversible. (F) Neovascularization scores were significantly higher for both non-crosslinked meshes (Veritas and AlloDerm) at 1 and 6 months compared with both crosslinked meshes (Permacoland Peri-Guard); p < 0.05. By 12 months, however, Veritas and AlloDerm reached significance only in comparison with Peri-Guard, but not Permacol (p < 0.01).